Search Results1-20 of  35

  • 1 / 2
  • Muro Kei ID: 9000264861945

    Articles in CiNii:1

    • Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer (2014)
  • Muro Kei ID: 9000266435624

    Articles in CiNii:1

    • A phase Ⅱ study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus : The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) (2014)
  • Muro Kei ID: 9000329006934

    Articles in CiNii:1

    • Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW : a randomized clinical trial in second-line treatment of gastric cancer (2016)
  • Muro Kei ID: 9000361678910

    Articles in CiNii:1

    • Comprehensive Registry of Esophageal Cancer in Japan, 2010 (2017)
  • Muro Kei ID: 9000380492858

    Articles in CiNii:1

    • Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naive metastatic gastric/gastroesophageal junction cancer (2018)
  • Muro Kei ID: 9000396179069

    Articles in CiNii:1

    • Comprehensive Registry of Esophageal Cancer in Japan, 2011 (2018)
  • Muro Kei ID: 9000398029930

    Articles in CiNii:1

    • First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer : a multicenter propensity score matched study (2018)
  • Muro Kei ID: 9000398634466

    Articles in CiNii:1

    • Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan (2018)
  • Muro Kei ID: 9000399574888

    Articles in CiNii:1

    • Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer : an exploratory analysis of the phase Ⅲ ABSOLUTE trial (2019)
  • Muro Kei ID: 9000401420817

    Articles in CiNii:1

    • A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2) (2019)
  • Muro Kei ID: 9000403259781

    Articles in CiNii:1

    • Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer : the JAVELIN Solid Tumor JPN trial (2019)
  • Muro Kei ID: 9000403259806

    Articles in CiNii:1

    • Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma : results from the phase Ⅱ nonrandomized KEYNOTE-059 study (2019)
  • Muro Kei ID: 9000403290252

    Articles in CiNii:1

    • Comprehensive registry of esophageal cancer in Japan, 2012 (2019)
  • Muro Kei ID: 9000403921182

    Articles in CiNii:1

    • Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G (2016)
  • Muro Kei ID: 9000406185117

    Articles in CiNii:1

    • Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial : a randomized phase Ⅲ clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer (2020)
  • Muro Kei ID: 9000409014726

    Articles in CiNii:1

    • A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2) : 2-year update data (2020)
  • Kei Muro ID: 9000408572236

    Articles in CiNii:1

    • Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors (2019)
  • Kei Muro ID: 9000408572305

    Articles in CiNii:1

    • Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial) (2019)
  • MURO Kei ID: 9000001019634

    Department of Internal Medicine, National Cancer Center Hospital East (1996 from CiNii)

    Articles in CiNii:1

    • Treatment for Locally Advanced Esophageal Carcinoma Complicated by Fistulas: Case Report (1996)
  • MURO Kei ID: 9000001122315

    Department of Clinical Oncology, Aichi Cancer Center Hospital (2012 from CiNii)

    Articles in CiNii:10

    • Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer (2003)
    • Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer (2004)
    • Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil (2004)
  • 1 / 2
Page Top